미국의 멀티오믹스 서비스 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 유형별, 용도별, 최종 용도별, 부문 예측(2025-2033년)

U.S. Multiomics Services Market Growth & Trends:

The U.S. multiomics services market is projected to reach USD 1.66 billion by 2033, growing at a CAGR of 17.10% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market is expanding rapidly, driven by the growing demand for integrated biological data to enhance disease understanding and accelerate the development of personalized therapies. Advancements in multiomics technologies, such as genomics, proteomics, metabolomics, and transcriptomics, are reshaping how complex diseases, including cancer, neurodegenerative disorders, and chronic conditions, are diagnosed and treated. Increased research funding and the rise of precision medicine are key factors fueling the market's growth.

Integrating AI and machine learning further accelerates the interpretation of complex datasets, enabling faster, more accurate decision-making in drug development and clinical diagnostics. These advancements allow researchers to analyze large-scale, integrated datasets from multiple biological layers, offering a comprehensive view of disease mechanisms and facilitating the identification of new biomarkers.

The market's growth is also driven by the increasing application of multiomics across various sectors, including pharmaceutical development, academic research, and clinical diagnostics. The need for personalized and targeted therapies in oncology, neurology, and rare disease treatments has created a strong demand for multiomics services. With evolving regulatory requirements, companies are expanding their service offerings and investing in innovations that streamline the research and clinical workflows, ensuring high-quality and compliant multiomics services.

As multiomics technologies evolve, the U.S. multiomics services market is positioned to advance biomedical research, accelerate drug discovery, and improve patient outcomes in precision health solutions worldwide.

U.S. Multiomics Services Market Report Highlights:

• By services, research services dominated the U.S. multiomics services market in 2024, accounting for 67.44% of the market share. Researchers are leveraging multiomics approaches to explore complex biological processes, discover new biomarkers, and gain deeper insights into disease mechanisms. As the need for comprehensive, integrated biological data grows in areas like oncology, neurology, and rare diseases, research services play a central role in advancing scientific knowledge and therapeutic innovation.
• By type, bulk multiomics services held the largest market share in 2024, accounting for 77.01% of the market. This dominance can be attributed to the growing demand for large-scale multiomics analysis in drug discovery, biomarker development, and clinical diagnostics. Bulk multiomics services offer comprehensive, scalable solutions for analyzing large datasets, integrating genomics, proteomics, and metabolomics information to enhance understanding of complex diseases. The ability to handle large volumes of data with high precision and efficiency positions bulk multiomics as a key service offering for pharmaceutical companies, research institutions, and clinical labs.
• By application, drug discovery & development dominated the U.S. multiomics services market in 2024, capturing 35.52% of the market share. Multiomics is increasingly being integrated into the drug development pipeline, allowing for more accurate identification of therapeutic targets, optimization of drug formulations, and a better understanding of drug efficacy and safety. This application continues to be a major driver in the market due to the growing focus on precision medicine, particularly in oncology, neurology, and immunology. The ability to provide a holistic view of disease mechanisms and predict patient responses to treatment enhances the success rate of drug discovery and clinical trials.
• By end use, pharmaceutical & biotechnology companies dominated the U.S. multiomics services market in 2024, accounting for 44.83% of the market share. These companies are at the forefront of adopting multiomics services to support drug discovery, biomarker development, and personalized medicine. The demand for high-quality, integrated multiomics data is critical in streamlining the development of innovative therapies and improving the precision of clinical trials. Ongoing collaborations between pharmaceutical companies, biotechnology firms, and multiomics service providers are helping to accelerate the development of next-generation therapies and expand the applications of multiomics across various therapeutic areas.
• In April 2025, Source BioScience collaborated with CCL to strengthen its genomic testing and precision medicine capabilities to advance diagnostic solutions and drive innovations in critical healthcare.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Service Segment
  • 1.2.2. Type Segment
  • 1.2.3. Application Segment
  • 1.2.4. End Use Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Multiomics Services Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Multiomics Services Market: Service Business Analysis

• 4.1. Service Segment Dashboard
• 4.2. U.S. Multiomics Services Market Service Movement Analysis
• 4.3. U.S. Multiomics Services Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
• 4.4. Research Services
  • 4.4.1. U.S. Research Services based Market, 2021 - 2033 (USD Million)
• 4.5. Data Analysis Services
  • 4.5.1. U.S. Data Analysis Services Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Multiomics Services Market: Type Business Analysis

• 5.1. Type Segment Dashboard
• 5.2. U.S. Multiomics Services Market Type Movement Analysis
• 5.3. U.S. Multiomics Services Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 5.4. Single-cell Multiomics
  • 5.4.1. U.S. Single-cell Multiomics Market, 2021 - 2033 (USD Million)
• 5.5. Bulk Multiomics
  • 5.5.1. U.S. Bulk U.S. Multiomics Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Multiomics Services Market: Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. U.S. Multiomics Services Market Application Movement Analysis
• 6.3. U.S. Multiomics Services Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Biomarker Discovery Market
  • 6.4.1. U.S. Biomarker Discovery Market, 2021 - 2033 (USD Million)
• 6.5. Drug Discovery & Development
  • 6.5.1. U.S. Drug Discovery & Development Market, 2021 - 2033 (USD Million)
• 6.6. Synthetic Biology
  • 6.6.1. U.S. Synthetic Biology Market, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. U.S. Multiomics Services Market: End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. U.S. Multiomics Services Market End Use Movement Analysis
• 7.3. U.S. Multiomics Services Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Pharmaceutical and Biotechnology Companies
  • 7.4.1. U.S. Pharmaceutical and Biotechnology Companies Devices Market, 2021 - 2033 (USD Million)
• 7.5. Academic & Research Institutes
  • 7.5.1. U.S. Academic & Research Institutes Market, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Bio-Techne
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Service Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. CD Genomics
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Service Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. RayBiotech, Inc.
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Service Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. . Creative Proteomics
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Service Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Psomagen
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Service Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Source BioScience
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Service Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Persistent Systems
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Service Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Metware Biotechnology Inc.
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Service Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Dalton Bioanalytics Inc.
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Service Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Sapient Bioanalytics, LLC.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Service Benchmarking
    • 8.4.10.4. Strategic Initiatives